Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.38 -0.08 (-0.14%)
Official Closing Price Updated: 7:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,642,677
Open 56.72
Bid (Size) 56.34 (1)
Ask (Size) 56.40 (3)
Prev. Close 56.46
Today's Range 55.77 - 57.18
52wk Range 45.05 - 138.62
Shares Outstanding N/A
Dividend Yield 3.90%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga

Performance

YTD
-35.6%
-35.6%
1 Month
+15.5%
+15.5%
3 Month
-20.5%
-20.5%
6 Month
-35.6%
-35.6%
1 Year
-58.6%
-58.6%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock
Via Chartmill
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Via The Motley Fool
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Via Benzinga
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Via Benzinga
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?
Via Stocktwits
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
Via Investor's Business Daily
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Via Investor's Business Daily
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears
Via Benzinga
Stevens Capital Closes Out Position in Eli Lilly
Via The Motley Fool
2 Dividend Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Economy
2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 56.38
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/02/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.